Supreme Court Regulations May Impact Insurance Compliance
The Supreme Court's rulings and CMS drug price negotiations may impact insurance compliance. Explore regulations affecting the insurance industry today.
AHA Responds to CMS on New Drug Pricing Model
Explore AHA's response to the CMS's proposed drug pricing model aiming to lower costs under Medicare Part B while addressing hospital concerns.
Trump Administration's MFN Drug Pricing Initiatives Impacting Medicare
Explore the implications of the Trump Administration's MFN pricing and CMS's GLOBE and GUARD models on Medicare and pharmaceutical manufacturers. Act now!
Oregon Reinstates Drug Price Reporting for Insurance Compliance
Oregon reinstates annual price increase reports for drug pricing transparency. Learn how this affects insurance compliance, risk management, and industry standards.
The Impact of PBMs on Medicare and Medicaid: A Study Overview
Discover how PBMs influence Medicare and Medicaid markets, focusing on drug prices, regulation, and accountability in healthcare practices.
New Federal Reforms on Pharmacy Benefit Managers Impact Health Plans
Discover how the new federal reforms on pharmacy benefit managers are reshaping health plans and Medicare Part D with a focus on transparency and compliance.
Healthcare Cost Changes in 2026: Implications for the Insurance Industry
Explore how the 2026 healthcare cost changes will impact insurance, with strategic insights on Medicare, ACA, and new drug pricing structures.
CMS Updates on Medicare Drug Price Negotiation and 340B Rebate Litigation
CMS announces changes to Medicare drug price negotiations; ongoing litigation surrounds 340B rebate model and state drug pricing laws, affecting Medicare Advantage plans and Part D reimbursement.
House GOP Proposes Employer Insurance Expansion, PBM Controls as ACA Subsidies Expire
With enhanced ACA subsidies expiring, House Republicans propose expanding employer insurance access and regulating PBMs to address drug costs, while bipartisan efforts seek subsidy extensions.
Medicare Drug Price Negotiations Yield Significant Savings for 15 Key Medications
Pharmaceutical companies agree to reduce Medicare prices for 15 prescription drugs, potentially saving billions in taxpayer and patient costs under new negotiation rules starting in 2027.